Guardant Health Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
GH$155.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (unaudited)
(in thousands, except per share data)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenue: | ||||
| Precision oncology testing | $180,604 | $133,423 | $503,351 | $372,060 |
| Development services and other | 10,872 | 9,607 | 33,851 | 36,834 |
| Total revenue | 191,476 | 143,030 | 537,202 | 408,894 |
| Costs and operating expenses: | ||||
| Cost of precision oncology testing | 66,095 | 53,648 | 191,116 | 148,111 |
| Cost of development services and other | 8,394 | 3,966 | 21,090 | 16,424 |
| Research and development expense | 87,306 | 93,851 | 254,210 | 277,338 |
| Sales and marketing expense | 97,880 | 68,934 | 260,172 | 216,100 |
| General and administrative expense | 49,129 | 36,174 | 128,243 | 118,135 |
| Total costs and operating expenses | 308,804 | 256,573 | 854,831 | 776,108 |
| Loss from operations | (117,328) | (113,543) | (317,629) | (367,214) |
| Interest income | 13,257 | 11,690 | 42,038 | 21,477 |
| Interest expense | (646) | (644) | (1,936) | (1,933) |
| Other income (expense), net | (3,007) | 16,885 | (47,272) | 56,490 |
| Loss before provision for income taxes | (107,724) | (85,612) | (324,799) | (291,180) |
| Provision for income taxes | 30 | 490 | 568 | 1,226 |
| Net loss | $(107,754) | $(86,102) | $(325,367) | $(292,406) |
| Net loss per share, basic and diluted | $(0.88) | $(0.73) | $(2.66) | $(2.66) |
| Weighted-average shares used in computing net loss per share, basic and diluted | 123,051 | 117,736 | 122,406 | 109,791 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.